Actionable news
All posts from Actionable news
Actionable news in KITE: KITE PHARMA Inc,

Kite Pharma (KITE) Q2 Loss Narrower Than Expected, Sales Beat

Kite Pharma, Inc. (KITE - Free Report) is a development-stage company focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer. Kite uses eACT to genetically modify T cells to express either CARs or TCRs. The modified T-cells are designed to recognize and destroy cancer cells. Immuno-oncology is a hot therapeutic area with huge commercial potential.

Kite Pharma’s lead drug axicabtagene ciloleucel is currently under priority review in the U.S. for treating aggressive non-Hodgkin lymphoma (NHL) with a FDA decision expected on Nov 29.

Axicabtagene ciloleucel is expected to be approved and launched in the U.S this year. In Europe, a regulatory application was filed last week with...